Search

Displaying results 1721 - 1730 of 7058 in total
  1. Drug

    Tegeprotafib

    go.drugbank.com/drugs/DB21665
    Experimental

    Tegeprotafib is a small molecule drug. Tegeprotafib has a monoisotopic molecular weight of 326.04 Da.

  2. Drug

    Vamagloxistat

    go.drugbank.com/drugs/DB21666
    Experimental

    Vamagloxistat is a small molecule drug. Vamagloxistat has a monoisotopic molecular weight of 371.11 Da.

  3. Drug

    Milpecitinib

    go.drugbank.com/drugs/DB21676
    Experimental

    Milpecitinib is a small molecule drug. Milpecitinib has a monoisotopic molecular weight of 380.13 Da.

  4. Drug

    Claziprotamide

    go.drugbank.com/drugs/DB21687
    Experimental

    Claziprotamide is a small molecule drug. Claziprotamide has a monoisotopic molecular weight of 374.13 Da.

  5. Drug

    Calcium glycerophosphate

    go.drugbank.com/drugs/DB11264
    Approved

    The commercial product is a mixture of calcium beta-, and D-, and L -alpha-glycerophosphate. … Calcium glycerophosphate is a [DB01373] salt of glycerophosphoric acid that forms a white, fine, slightly hygroscopic powder.

    Mixtures: Alsimine W Vitamins A D
  6. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L56179] This approval was expedited following receipt of an FDA Commissioner’s National Priority Voucher. … Zenocutuzumab is a low-fucose humanized full-length immunoglobulin G1 (IgG1) bispecific HER2- and HER3-directed bispecific antibody.

  7. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). … It was also approved by FDA and EMA in 2016. It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]

  8. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    _PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.

    Synonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-
  9. Drug

    Pomalidomide

    go.drugbank.com/drugs/DB08910
    ApprovedInvestigational

    FDA approved on February 8, 2013.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  10. Drug

    Canagliflozin

    go.drugbank.com/drugs/DB08907
    ApprovedInvestigational

    [FDA label]. … 2 diabetes mellitus [L5897], [FDA label].